Caricamento...
CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy
Cancer immunotherapy has been emerged as a promising strategy for treatment of a broad spectrum of malignancies ranging from hematological to solid tumors. One of the principal approaches of cancer immunotherapy is transfer of natural or engineered tumor-specific T-cells into patients, a so called “...
Salvato in:
| Pubblicato in: | Cancer Cell Int |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7493839/ https://ncbi.nlm.nih.gov/pubmed/32973401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-020-01546-8 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|